Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Multiple Myeloma Patients With Renal Insufficiency
NCT02833610Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2016
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Primary endpoint: Serum C-telopeptide cross-link of type 1 collagen at 2 years. Started Aug 2016; status: completed.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02833610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833610.